Donaldson Janine, Jacek Tomasz, Wychowański Piotr, Zaworski Kamil, Szkopek Dominika, Woliński Jarosław, Grujic Danica, Pierzynowski Stefan, Pierzynowska Kateryna
School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Parktown, Johannesburg 2193, South Africa.
Anara AB, 23132 Trelleborg, Sweden.
Int J Mol Sci. 2025 Feb 20;26(5):1818. doi: 10.3390/ijms26051818.
Two different diets able to induce dietary hyperammonaemia (a methionine-choline-deficient (MCD) diet and a methionine-deficient diet enriched with ammonium acetate (MAD + 20% ammonium acetate)) were tested in a rat model. The diets were shown to have different modes of action, inducing significant hyperammonaemia (HA) and growth retardation in the rats, with different metabolic consequences. The MCD diet resulted in the development of endogenous HA, with a decrease in bilirubin levels and an increase in hepatic fat content. In contrast, the MAD + 20% ammonium acetate diet increased circulating ALP and haptoglobin levels and decreased liver mass. The above results suggest that the MCD diet deteriorated the liver function of the rats, resulting in the development of endogenous HA, while the MAD diet caused moderate changes in liver metabolism, resulting in the development of exogenous HA. Interestingly, the commonly used oral treatments Lactulose and Rifaximin did not ameliorate hyperammonaemia during or after the treatment period. In conclusion, even though the diets used in the current study caused somewhat similar hyperammonaemia, they seemed to provoke different metabolic consequences. The latter can have an impact on the severity of the resulting hyperammonaemia and thus on the hyperammonaemia-induced encephalopathy, resulting in the development of distinguishing cognitive and metabolic (liver) effects compared to other forms of encephalopathy. We hypothesized that these rat models, with significantly increased serum ammonia levels, along with different liver injuries, could serve as a suitable double animal model for the testing of new, oral enzyme therapies for hepatic encephalopathy in future studies.
在大鼠模型中测试了两种能够诱发饮食性高氨血症的不同饮食(一种蛋氨酸 - 胆碱缺乏(MCD)饮食和一种富含乙酸铵的蛋氨酸缺乏饮食(MAD + 20%乙酸铵))。结果表明,这两种饮食具有不同的作用方式,可在大鼠中诱发显著的高氨血症(HA)和生长迟缓,并产生不同的代谢后果。MCD饮食导致内源性HA的发生,胆红素水平降低,肝脂肪含量增加。相比之下,MAD + 20%乙酸铵饮食使循环碱性磷酸酶(ALP)和触珠蛋白水平升高,肝脏质量降低。上述结果表明,MCD饮食使大鼠肝功能恶化,导致内源性HA的发生,而MAD饮食引起肝脏代谢的适度变化,导致外源性HA的发生。有趣的是,常用的口服治疗药物乳果糖和利福昔明在治疗期间或治疗后并未改善高氨血症。总之,尽管本研究中使用的饮食引起了 somewhat 相似的高氨血症,但它们似乎引发了不同的代谢后果。后者可能会影响由此产生的高氨血症的严重程度,进而影响高氨血症诱发的脑病,与其他形式的脑病相比,导致明显的认知和代谢(肝脏)效应的发展。我们假设,这些血清氨水平显著升高且伴有不同肝损伤的大鼠模型,可作为未来研究中测试用于肝性脑病的新型口服酶疗法的合适双动物模型。